Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Elba Meza"'
Autor:
Julio Vallejos, Rodrigo Zoni, María Bangher, Silvina Villamandos, Angelina Bobadilla, Fabian Plano, Claudia Campias, Evangelina Chaparro Campias, Maria Fernanda Medina, Fernando Achinelli, Hector Andres Guglielmone, Jorge Ojeda, Diego Farizano Salazar, Gerardo Andino, Pablo Kawerin, Silvana Dellamea, Antonia Cristina Aquino, Victor Flores, Carolina N. Martemucci, Silvina Maria Martinez, Juan Emanuel Segovia, Paola Itati Reynoso, Noelia Carolina Sosa, Mariana Elizabeth Robledo, Joaquina Maria Guarrochena, Maria Mercedes Vernengo, Natalia Ruiz Diaz, Elba Meza, María Gabriela Aguirre
Publikováno v:
BMC Infectious Diseases, Vol 21, Iss 1, Pp 1-11 (2021)
Abstract Background Severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) has changed our lives. The scientific community has been investigating re-purposed treatments to prevent disease progression in coronavirus disease (COVID-19) patients. O
Externí odkaz:
https://doaj.org/article/352f333976e94f65826dfd181b4c36a3
Autor:
Fernando Achinelli, Gerardo Andino, Maria Bangher, Paola Itati Reynoso, Antonia Cristina Aquino, Jorge Ojeda, Silvana Dellamea, Victor Flores, María Gabriela Aguirre, Elba Meza, Carolina N. Martemucci, Pablo Kawerin, Fabian Plano, Mariana Elizabeth Robledo, Claudia Campias, Hector Andres Guglielmone, Noelia Carolina Sosa, Evangelina Chaparro Campias, Rodrigo Zoni, Maria Mercedes Vernengo, Silvina Maria Martinez, Joaquina Maria Guarrochena, Natalia E. Ruiz Diaz, Diego Farizano Salazar, Julio Vallejos, Maria Fernanda Medina, Angelina Bobadilla, Silvina Villamandos, Juan Emanuel Segovia
Publikováno v:
BMC Infectious Diseases, Vol 21, Iss 1, Pp 1-11 (2021)
BMC Infectious Diseases
BMC Infectious Diseases
Background Severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) has changed our lives. The scientific community has been investigating re-purposed treatments to prevent disease progression in coronavirus disease (COVID-19) patients. Objective
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2288a32d35e0fef7930606a34739ab04
https://doaj.org/article/352f333976e94f65826dfd181b4c36a3
https://doaj.org/article/352f333976e94f65826dfd181b4c36a3
Autor:
Jorge Ojeda, Gerardo Andino, Fernanda Medina, Fabian Plano, Silvina Maria Martinez, Juan Emanuel Segovia, Maria Mercedes Vernengo, Claudia Campias, Angelina Bobadilla, Natalia E. Ruiz Diaz, Silvina Villamandos, Rodrigo Zoni, Victor Flores, Diego Farizano Salazar, Elba Meza, Hector Andres Guglielmone, Pablo Kawerin, Evangelina Chaparro Campias, Fernando Achinelli, Silvana Dellamea, Maria Bangher, Carolina N. Martemucci, Antonia Cristina Aquino, Julio Vallejos, María Gabriela Aguirre
Publikováno v:
Trials
Objectives To assess the efficacy of ivermectin in addition to standard treatment compared to standard treatment alone in reducing hospitalizations in the COVID-19 patient population. Trial design IVERCOR-COVID19 will be a single-center, prospective,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4a2602581f6e8775752e27c20f5d57e0
https://pubmed.ncbi.nlm.nih.gov/33234158
https://pubmed.ncbi.nlm.nih.gov/33234158